VF
SRPT icon

VitalStone Financial’s Sarepta Therapeutics SRPT Stock Holding History

VitalStone Financial’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$327K Buy
+2,622
New +$362K 0.22% 86

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

VitalStone Financial's SRPT Position: Q3 2024 in Review

VitalStone Financial opened a new position in Sarepta Therapeutics (SRPT) in Q3 2024: 2,622 shares worth $327K. The stake represents 0.22% of the portfolio and ranks #86 among its holdings.

458 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • VitalStone Financial held 2,622 shares of Sarepta Therapeutics worth $327K as of Q3 2024.
  • Sarepta Therapeutics was a new VitalStone Financial position in Q3 2024.
  • Sarepta Therapeutics made up 0.22% of VitalStone Financial's portfolio in Q3 2024, its #86 holding.
  • 458 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on VitalStone Financial's 13F filing for Q3 2024, filed 11 Oct 2024.